The 2011 Fukushima nuclear disaster in Japan inflamed worldwide fears of nuclear contamination. Governments refocused attention on experimental medications to protect humans from radiation damage. U.S. biotech companies backed by grants from the Pentagon led the field. Their efforts were bogged down in promising trials with lab animals, which chronically failed in humans. Meanwhile, in Bordeaux, France, the freak discovery of a retired nuclear power worker with a suspected natural resistance to nuclear radiation offered the prospect of a dramatic breakthrough. As word of the discovery spread, danger closed in. Which competitors from as far afield as London, Tel Aviv, Tehran, and Pittsburgh were behind the abductions, thefts of scientific material, and patent disputes blocking the French effort? Ultimately the genetic mysteries behind the discovery were much more complex than anyone imagined, threatening to destroy all efforts at a solution. Ian Greenham was born and...

Под заказ:
	OZON.ru - 1088 руб.	Перейти

Рейтинг книги: 4 из 5, 5 голос(-ов).